Efficacy of Bifidobacterium Agent on Patients with Irritable Bowel Syndrome: A Randomized Controlled Trial - IBS-Bb-RCT

Fukudo Shin0 个研究点目标入组 70 人开始时间: 2021年9月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Subjects with IBS diagnosed with Rome IV criter ia
•2. Subjects who want to receive IBS treatment of t he first step in clinical practice guideline of JSGE 2 020
•3. Aged 18-75 years at the time of informed conse nt
•4. Provision of written informed consent

•1. Major abdominal surgery (except appendectomy or hysterectomy)
•2. History of inflammatory bowel disease, ischemic colitis, malignant tumor
•3. Severe neurological complications (Parkinson's disease, Shy-Drager syndrome, schizophrenia, bip olar disorder)
•4. Use of probiotics within 4 weeks prior to randomization
•5. Allergy to probiotics
•6. Allergy to starch
•7. Severe complications (hepatic diseases, serious cardiovascular diseases, hematological diseases, metabolic diseases or malignant neoplasms)
•8. Pregnancy, breastfeeding or planning on becom ing pregnant throughout the course of the study
•9. Unable to take MRI
•10. Severe disturbance in lifestyle
•11. No existence of abdominal pain or no bowel dysfunction
•12. Gdaduate school students in the department of the principal investigator
•13. Lack of suitability for participation in the study for any reason as judged by the investigator

发起方

Fukudo Shin